ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101
December 03, 2018Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is -
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101
December 03, 2018Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is -
Allergan, Editas Medicine to Jointly Develop EDIT-101
August 08, 2018Allergan and Editas Medicine announced Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10.....
Pharma Sources Insight January 2025
